Sanofi (FRA:SNW)
Germany · Delayed Price · Currency is EUR | Market Cap | 103.06B |
| Revenue (ttm) | 45.74B |
| Net Income (ttm) | 9.13B |
| Shares Out | n/a |
| EPS (ttm) | 7.36 |
| PE Ratio | 11.29 |
| Forward PE | 10.42 |
| Dividend | 3.92 (4.64%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 456 |
| Average Volume | 4,849 |
| Open | 85.32 |
| Previous Close | 84.53 |
| Day's Range | 85.01 - 85.77 |
| 52-Week Range | 77.85 - 110.82 |
| Beta | n/a |
| RSI | 53.84 |
| Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi (SNY) Receives Upgrade from Deutsche Bank | SNY Stock News
Sanofi (SNY) Receives Upgrade from Deutsche Bank | SNY Stock News
Sanofi CEO: AI might beat IQ, not EQ — but never say never
We underestimate the scale of the AI learning curve, says Paul Hudson, CEO of Sanofi.
Thermo Fisher Scientific Completes Acquisition of Sanofi’s Ridgefield, New Jersey Site
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in ...
Sanofi's (SNY) Wayrilz Gains FDA Approval for ITP Treatment
Sanofi's (SNY) Wayrilz Gains FDA Approval for ITP Treatment
Sanofi wins FDA nod for Wayrilz in bleeding disorder thrombocytopenia
Now Is The Time To Buy This High-Yielding Trio
The focus of today will be on CMCSA, AES, and SNY. The trifecta provides a reasonably secure 4.5% average yield, an A- average S&P credit rating, and is 33% undervalued. Comcast Corporation could be s...
US FDA approves Sanofi's drug for a rare blood disorder
The U.S. Food and Drug Administration has approved Sanofi's drug to treat a type of blood disorder, the company said on Friday, in a sign that the French drugmaker's $3.7 billion bet on the treatment ...
Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA...
Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA...
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ad...
Sanofi gets EU orphan designation for rilzabrutinib
Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...
Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients . The initiative , announced Tuesday, combines governme...
Sanofi reportedly halts sales of cholesterol drug Praluent in China amid limited availability
Sanofi stops supply of high cholesterol drug to China due to limited availability
Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to lim...
Sanofi: Playing To Win
Emcure Pharmaceuticals Reports Strong Q1 FY26 Results with 16% Revenue Growth and 41% Jump in Profit
Emcure Pharmaceuticals reported a strong Q1 FY26 performance with a 15.7% YoY rise in revenue to ₹2,101 crore and a 41% jump in PAT to ₹215 crore. Robust growth was seen across both domestic and inter...
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).
What's Driving the Market Sentiment Around Sanofi?
Sanofi's (NYSE: SNY) short percent of float has fallen 15.0% since its last report. The company recently reported that it has 3.67 million shares sold short , which is 0.17% of all regular shares tha...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Arrowhead unit sells rights for plozasiran to Sanofi in Greater China
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Sanofi (SNY) Q2 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of Specialty...